Compare · APYX vs WST
APYX vs WST
Side-by-side comparison of Apyx Medical Corporation (APYX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APYX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 141.1x APYX ($179.4M).
- Over the past year, APYX is up 92.8% and WST is up 70.4% - APYX leads by 22.3 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 2 for APYX).
- WST has more recent analyst coverage (18 ratings vs 9 for APYX).
- Company
- Apyx Medical Corporation
- West Pharmaceutical Services Inc.
- Price
- $4.26-2.07%
- $358.18-1.11%
- Market cap
- $179.4M
- $25.31B
- 1M return
- +1.67%
- +8.72%
- 1Y return
- +92.76%
- +70.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 5
- Recent ratings
- 9
- 18
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest APYX
- H.C. Wainwright initiated coverage on Apyx Medical with a new price target
- Director Waldman Lawrence covered exercise/tax liability with 5,024 shares and exercised 12,000 shares at a strike of $1.88 (SEC Form 4)
- SEC Form DEF 14A filed by Apyx Medical Corporation
- Chief Operating Officer Roman Shawn David exercised 15,000 shares at a strike of $3.23 and covered exercise/tax liability with 10,533 shares (SEC Form 4)
- SEC Form 8-K filed by Apyx Medical Corporation
- SEC Form 4 filed by Director Levine Wendy Lauren
- Director Vizirgianakis Stavros G. was granted 450,000 units of Restricted Stock Units, increasing direct ownership by 26% to 2,196,191 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Goodwin Charles D. Ii
- SEC Form 4 filed by Chief Financial Officer Hill Matthew C
- SEC Form 4 filed by Chief Operating Officer Roman Shawn David
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits